Rx Nutrition Resource Center

Rx Nutrition Resource Center

Disclosures: Scholl is employed by the Helmsley Charitable Trust.
November 25, 2020
1 min read

Helmsley awards $4.7 million for Crohn's diet therapy research

Disclosures: Scholl is employed by the Helmsley Charitable Trust.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The Leona M. and Harry B. Helmsley Charitable Trust awarded nearly $4.7 million to fund three studies designed to explore dietary interventions for Crohn’s disease, according to a press release.

“Previous studies strongly suggest that dietary interventions may be beneficial in Crohn’s disease, but clear evidence-based recommendations are lacking,” Paul Scholl, program director of the Helmsley Charitable Trust Crohn’s disease program, said in the release. “By directly evaluating the effects of specific dietary regimens in preventing and treating Crohn’s disease, these new studies will provide much needed data that can guide future research and inform dietary guidelines for people living with this disease.”

First, the Trust awarded $1.9 million to the COmbinAtion therapy of dieT with biologicalS for Crohn’s disease (OATS) study. The OATS study will investigate the safety and efficacy of the Food influence on the Intestinal microbiota diet, also known as the FIT diet. Specifically, it will study the diet as an add-on therapy during induction and maintenance therapies of biologic therapies in patients with CD.

Second, the Trust awarded $1.4 million to the Inflammatory Bowel Disease Mediterranean Diet (IBDMED) project, which will evaluate the effect of the program on patients with newly diagnosed CD in India and compare its effects to the same intervention performed in Israel.

Finally, the trust awarded $1.3 million to the Preventing IBD ONset in Individuals at Risk (PIONIR) trial. The study will expand ongoing research aimed at evaluating the effectiveness of the “Tasty & Healthy” dietary approach for the induction and remission of CD.